Revelation Biosciences, Inc. (NASDAQ:REVB) Sees Large Growth in Short Interest

Revelation Biosciences, Inc. (NASDAQ:REVBGet Free Report) was the target of a large increase in short interest during the month of January. As of January 31st, there was short interest totalling 120,200 shares, an increase of 526.0% from the January 15th total of 19,200 shares. Based on an average trading volume of 214,400 shares, the days-to-cover ratio is presently 0.6 days. Currently, 30.8% of the shares of the stock are short sold.

Revelation Biosciences Trading Down 2.9 %

Shares of NASDAQ REVB traded down $0.08 during mid-day trading on Monday, reaching $2.70. The company had a trading volume of 185,532 shares, compared to its average volume of 514,597. The stock has a market cap of $567,000.00, a price-to-earnings ratio of -0.19 and a beta of 0.37. The business’s 50-day moving average is $12.99 and its 200-day moving average is $18.07. Revelation Biosciences has a 52 week low of $2.40 and a 52 week high of $87.90.

Revelation Biosciences (NASDAQ:REVBGet Free Report) last released its quarterly earnings results on Thursday, November 9th. The company reported ($12.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($9.00) by ($3.30). As a group, equities research analysts forecast that Revelation Biosciences will post -38.74 earnings per share for the current year.

Hedge Funds Weigh In On Revelation Biosciences

Several institutional investors and hedge funds have recently modified their holdings of REVB. Ergoteles LLC purchased a new position in shares of Revelation Biosciences in the first quarter worth about $25,000. State Street Corp acquired a new stake in Revelation Biosciences in the 3rd quarter valued at about $28,000. CVI Holdings LLC purchased a new position in Revelation Biosciences in the 1st quarter worth approximately $43,000. Virtu Financial LLC acquired a new position in shares of Revelation Biosciences during the 2nd quarter worth approximately $63,000. Finally, Hudson Bay Capital Management LP purchased a new stake in shares of Revelation Biosciences in the first quarter valued at approximately $142,000. Institutional investors and hedge funds own 12.80% of the company’s stock.

Revelation Biosciences Company Profile

(Get Free Report)

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-100, a potential therapy for the prevention and treatment of healthcare-associated bacterial infection resulting from surgery, severe burns, urinary tract infection, sepsis, and antibiotic resistance; REVTx-200, a potential intranasal therapy; and REVTx-300, a potential therapy for the treatment of chronic organ disease, including chronic kidney disease.

Read More

Receive News & Ratings for Revelation Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revelation Biosciences and related companies with's FREE daily email newsletter.